Clinical Trial Update: A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer [Phase 1, Phase 2]

View source ↗

Summary

Memorial Sloan Kettering Cancer Center conducted a Phase 1/2 trial of Mirdametinib alone or with Fulvestrant in solid tumors including breast cancer, with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• Fulvestrant (fulvestrant)
• Mirdametinib (mirdametinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer, Breast Cancer Stage IV | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-07-09